Angiogenesis inhibitor DC101 delays growth of intracerebral glioblastoma but induces morbidity when combined with irradiation

Cancer Letters

Volumn 285, Issue 1, 2009, Pages 39-45

  Verhoeff, Joost J C ^a   Stalpers, Lukas J A ^a   Van Noorden, Cornelis J F ^b   Troost, Dirk ^b   Ramkema, Marja D ^b   van Bree, Chris ^a   Song, Ji Ying ^c   Donker, Mila ^b   Chekenya, Martha ^d   Vandertop, W Peter ^b   Richel, Dick J ^a   van Furth, Wouter R ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d UNIVERSITY OF BERGEN   (Norway)

Author keywords

Angiogenesis inhibition; Glioma; Intracranial; Nude mouse; Radiotherapy

Indexed keywords

MONOCLONAL ANTIBODY DC101; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CONTROLLED STUDY; GLIOBLASTOMA; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKULL IRRADIATION; SURVIVAL RATE; TUMOR REGRESSION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; BRACHYTHERAPY; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOTHERAPY, ADJUVANT; CRANIAL IRRADIATION; FEMALE; GLIOBLASTOMA; HUMANS; MICE; MICE, NUDE; NECROSIS; NEOVASCULARIZATION, PATHOLOGIC; RADIOTHERAPY, ADJUVANT; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

MUS; MUS MUSCULUS;

EID: 70349281453     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.04.038     Document Type: Article

References (43)

1. Hochberg F.H., and Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology 30 (1980) 907-911
2. Ferrara N., and Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev. 18 (1997) 4-25
3. Holash J., Wiegand S.J., and Yancopoulos G.D. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 18 (1999) 5356-5362
4. Toi M., Matsumoto T., and Bando H. Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. Lancet Oncol. 2 (2001) 667-673
5. Shaked Y., Ciarrocchi A., Franco M., Lee C.R., Man S., Cheung A.M., Hicklin D.J., Chaplin D., Foster F.S., Benezra R., and Kerbel R.S. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313 (2006) 1785-1787
6. Kozin S.V., Boucher Y., Hicklin D.J., Bohlen P., Jain R.K., and Suit H.D. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res. 61 (2001) 39-44
7. Camphausen K., Purow B., Sproull M., Scott T., Ozawa T., Deen D.F., and Tofilon P.J. Orthotopic growth of human glioma cells quantitatively and qualitatively influences radiation-induced changes in gene expression. Cancer Res. 65 (2005) 10389-10393
8. MacDonald T.J., Taga T., Shimada H., Tabrizi P., Zlokovic B.V., Cheresh D.A., and Laug W.E. Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery 48 (2001) 151-157
9. Taillandier L., Antunes L., and Angioi-Duprez K.S. Models for neuro-oncological preclinical studies: solid orthotopic and heterotopic grafts of human gliomas into nude mice. J. Neurosci. Methods 125 (2003) 147-157
10. Blouw B., Song H., Tihan T., Bosze J., Ferrara N., Gerber H.P., Johnson R.S., and Bergers G. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 4 (2003) 133-146
11. Fomchenko E.I., and Holland E.C. Mouse models of brain tumors and their applications in preclinical trials. Clin. Cancer Res. 12 (2006) 5288-5297
12. Charalambous C., Hofman F.M., and Chen T.C. Functional and phenotypic differences between glioblastoma multiforme-derived and normal human brain endothelial cells. J. Neurosurg. 102 (2005) 699-705
13. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
14. Nieder C., Wiedenmann N., Andratschke N., and Molls M. Current status of angiogenesis inhibitors combined with radiation therapy. Cancer Treat. Rev. 32 (2006) 348-364
15. Gutin P.H., Iwamoto F.M., Beal K., Mohile N.A., Karimi S., Hou B.L., Lymberis S., Yamada Y., Chang J., and Abrey L.E. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int. J. Radiat. Oncol Biol. Phys. (2009)
16. Narayana A., Kelly P., Golfinos J., Parker E., Johnson G., Knopp E., Zagzag D., Fischer I., Raza S., Medabalmi P., Eagan P., and Gruber M.L. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J. Neurosurg. 110 (2009) 173-180
17. Verhoeff J.J., Stalpers L.J., Coumou A.W., Koedooder K., Lavini C., Van Noorden C.J., Haveman J., Vandertop W.P., and van Furth W.R. Experimental iodine-125 seed irradiation of intracerebral brain tumors in nude mice. Radiat. Oncol. 2 (2007) 38
18. Lund E.L., Bastholm L., and Kristjansen P.E. Therapeutic synergy of TNP-470 and ionizing radiation: effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenografts. Clin. Cancer Res. 6 (2000) 971-978
19. Hess C., Vuong V., Hegyi I., Riesterer O., Wood J., Fabbro D., Glanzmann C., Bodis S., and Pruschy M. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth. Br. J. Cancer 85 (2001) 2010-2016
20. Winkler F., Kozin S.V., Tong R.T., Chae S.S., Booth M.F., Garkavtsev I., Xu L., Hicklin D.J., Fukumura D., di Tomaso E., Munn L.L., and Jain R.K. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6 (2004) 553-563
21. Sarkaria J.N., Carlson B.L., Schroeder M.A., Grogan P., Brown P.D., Giannini C., Ballman K.V., Kitange G.J., Guha A., Pandita A., and James C.D. Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin. Cancer Res. 12 (2006) 2264-2271
22. Tabatabai G., Frank B., Wick A., Lemke D., von Kurthy G., Obermuller U., Heckl S., Christ G., Weller M., and Wick W. Synergistic antiglioma activity of radiotherapy and enzastaurin. Ann. Neurol. 61 (2007) 153-161
23. Chekenya M., Hjelstuen M., Enger P.O., Thorsen F., Jacob A.L., Probst B., Haraldseth O., Pilkington G., Butt A., Levine J.M., and Bjerkvig R. NG2 proteoglycan promotes angiogenesis-dependent tumor growth in CNS by sequestering angiostatin. FASEB J. 16 (2002) 586-588
24. Brekke C., Lundervold A., Enger P.O., Brekken C., Stalsett E., Pedersen T.B., Haraldseth O., Kruger P.G., Bjerkvig R., and Chekenya M. NG2 expression regulates vascular morphology and function in human brain tumours. Neuroimage 29 (2006) 965-976
25. Hovinga K.E., Stalpers L.J., van Bree C., Donker M., Verhoeff J.J., Rodermond H.M., Bosch D.A., and van Furth W.R. Radiation-enhanced vascular endothelial growth factor (VEGF) secretion in glioblastoma multiforme cell lines - a clue to radioresistance?. J. Neurooncol. 74 (2005) 99-103
26. Chekenya M., Krakstad C., Svendsen A., Netland I.A., Staalesen V., Tysnes B.B., Selheim F., Wang J., Sakariassen P.O., Sandal T., Lonning P.E., Flatmark T., Enger P.O., Bjerkvig R., Sioud M., and Stallcup W.B. The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling. Oncogene 27 (2008) 5182-5194
27. Bocci G., Man S., Green S.K., Francia G., Ebos J.M., du Manoir J.M., Weinerman A., Emmenegger U., Ma L., Thorpe P., Davidoff A., Huber J., Hicklin D.J., and Kerbel R.S. Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies. Cancer Res. 64 (2004) 6616-6625
28. Kunkel P., Ulbricht U., Bohlen P., Brockmann M.A., Fillbrandt R., Stavrou D., Westphal M., and Lamszus K. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res. 61 (2001) 6624-6628
29. Lamszus K., Brockmann M.A., Eckerich C., Bohlen P., May C., Mangold U., Fillbrandt R., and Westphal M. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin. Clin. Cancer Res. 11 (2005) 4934-4940
30. Yung Y.C., Cheshier S., Santarelli J.G., Huang Z., Wagers A., Weissman I., and Tse V. Incorporation of naive bone marrow derived cells into the vascular architecture of brain tumor. Microcirculation 11 (2004) 699-708
31. Jain R.K. Molecular regulation of vessel maturation. Nat. Med. 9 (2003) 685-693
32. Eskens F.A., and Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur. J. Cancer 42 (2006) 3127-3139
33. Kamba T., and McDonald D.M. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br. J. Cancer 96 (2007) 1788-1795
34. Peters N.A., Richel D.J., Verhoeff J.J., and Stalpers L.J. Bowel perforation after radiotherapy in a patient receiving sorafenib. J. Clin. Oncol. 26 (2008) 2405-2406
35. Dietrich J., Norden A.D., and Wen P.Y. Emerging antiangiogenic treatments for gliomas - efficacy and safety issues. Curr. Opin. Neurol. 21 (2008) 736-744
36. Williams K.J., Telfer B.A., Brave S., Kendrew J., Whittaker L., Stratford I.J., and Wedge S.R. ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity. Clin. Cancer Res. 10 (2004) 8587-8593
37. Ning S., Laird D., Cherrington J.M., and Knox S.J. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat. Res. 157 (2002) 45-51
38. Veronese M.L., Mosenkis A., Flaherty K.T., Gallagher M., Stevenson J.P., Townsend R.R., and O'Dwyer P.J. Mechanisms of hypertension associated with BAY 43-9006. J. Clin. Oncol. 24 (2006) 1363-1369
39. Goldman J., Rutkowski J.M., Shields J.D., Pasquier M.C., Cui Y., Schmokel H.G., Willey S., Hicklin D.J., Pytowski B., and Swartz M.A. Cooperative and redundant roles of VEGFR-2 and VEGFR-3 signaling in adult lymphangiogenesis. FASEB J. 21 (2007) 1003-1012
40. Fischer I., Cunliffe C.H., Bollo R.J., Raza S., Monoky D., Chiriboga L., Parker E.C., Golfinos J.G., Kelly P.J., Knopp E.A., Gruber M.L., Zagzag D., and Narayana A. High-grade glioma before and after treatment with radiation and avastin: initial observations. Neuro Oncol. 10 (2008) 700-708
41. Rubenstein J.L., Kim J., Ozawa T., Zhang M., Westphal M., Deen D.F., and Shuman M.A. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2 (2000) 306-314
42. Lamszus K., Kunkel P., and Westphal M. Invasion as limitation to anti-angiogenic glioma therapy. Acta Neurochir. Suppl. 88 (2003) 169-177
43. Martens T., Laabs Y., Gunther H.S., Kemming D., Zhu Z., Witte L., Hagel C., Westphal M., and Lamszus K. Inhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor-2. Clin. Cancer Res. 14 (2008) 5447-5458